Poly Medicure Ltd held its Q2 FY27 earnings call on November 05, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.
Strong Standalone Quarter; Consolidated Boosted by Acquisitions
Q2 FY 2026-2027 standalone revenue of Rs.488 crores (+17% YoY) — domestic Rs.170 crores (+22%), international Rs.313 crores (+15%); PAT Rs.92 crores at an 18.1% margin.
H1 FY 2026-2027 standalone revenue of Rs.919 crores (+15%) — domestic Rs.318 crores (+~20%), international Rs.595 crores; operating EBITDA Rs.255 crores (+20%); PAT Rs.180 crores (18% margin).
Consolidated H1 revenue of Rs.1,106 crores (+31%) — organic constant-currency revenue (ex-acquisitions) +14%, led by India (+19%) and Europe (+29%); Q2 consolidated revenue Rs.581 crores (+31%), PAT Rs.95 crores.
Q2 exceptional item of 96 million — reversal of contingent consideration under the PendraCare earnout structure after one contract development/manufacturing project failed regulatory and clinical trials and was shelved (per Rahul Gautam, President – Strategy and Corporate Development).
Net cash of Rs.460 crores — liquidity Rs.839 crores as of 30 September 2026 against consolidated debt of Rs.377 crores; H1 capex Rs.124 crores (Rs.110 Cr India, Rs.15 Cr overseas).
Standalone EBITDA margin guidance raised from 25-27% to 26-27.5% for FY 2026-2027 — consolidated EBITDA margin maintained at 23-25%; consolidated H1 EBITDA of Rs.266 crores (+19%) absorbs UK and Brazil subsidiary setup costs.
H1 gross margin rose 111 bps to 70.1% — despite management's initial guidance of 200-300 bps of FY 2026-2027 gross margin impact from West Asia crisis raw-material inflation; mitigated via proactive inventory management, calibrated price hikes, and high-value product focus.
Q2 gross margin normalized to 70.1% from 73.4% in Q1 FY 2026-2027 — Q1 benefited from 4-5% price hikes passed through and low-cost inventory carried at Q4 FY 2025-2026 cost basis; management did not quantify the split between inventory-gain reversal and RM inflation.
Standalone FY 2026-2027 gross margin guided at 68-69% (CFO Naresh Vijayvargiya), near the historical ~69% trend; consolidated gross margin expected to remain at 70%+ for FY 2026-2027.
Acquired-business margin roadmap — CTF already operates at 14-15% EBITDA margin and PendraCare was at 10-12% pre-crisis; management targets close to 20% EBITDA margin over a 3-5 year horizon (by FY 2029-2030 to FY 2031-2032) via synergies and operating leverage.
Consolidated margin floor not committed — on whether 23-25% holds above the lower end through FY 2029-2030, the MD did not commit; updated guidance will come closer to end of FY 2026-2027, with an aspiration to keep improving as the business grows.
Europe Rebounds Sharply; ROW Drags on West Asia Logistics
Europe grew close to 40% organically in Q2 FY 2026-2027 (management affirmed an analyst-cited ~50% figure) on top of a strong Q1; H1 Europe +29% — drivers include deeper customer/clinical engagement begun in FY 2025-2026, share gains as inventory normalizes, and 28-29 new customers added in H1.
ROW declined 7% in Q2 FY 2026-2027 (H1 -1.8%) on West Asia war-related geopolitical challenges; management characterized the weakness as logistical, not demand-driven — container availability, port access amid the Hormuz situation, and higher freight costs are leading customers to defer orders.
30 new international customers added in the last 6 months — alongside deeper share-of-wallet and cross-selling; international growth accelerated to 15% in Q2 from 10% in Q1 FY 2026-2027 (H1 export growth 12.5%).
CityF shortfall in CY 2026 stems from delayed public tenders in Italy — much of its European business is tender-driven; growth outside Italy (US, larger LATAM) is in line with expectations; YTD FY 2026-2027: PendraCare ~+10% YoY, CityF +3-4% YoY.
PendraCare's Middle East exposure is the key drag — almost 20% of FY 2026-2027 revenue came from the Middle East, including a reasonably large Iran exposure, where business has effectively come to a standstill; standalone it can grow high single digits, with a return to mid-teens expected with India integration and cost savings (period unspecified).
FenderCare recovery expected in CY 2027 / FY 2027-2028 — currently loss-making at the EBITDA level; war-driven RM inflation and loss of Middle East revenue (close to 20% of its 2025 revenue) hit the ~€10 million business; a large OEM customer of 15+ years grew ~40% in FY 2026-2027, recovering part of the lost revenue, with a large-OEM breakthrough adding revenue from mid CY 2027.
US tracking to $7-8 million in group-level sales in FY 2026-2027 — after a tariff-related standstill; one more 510(k) approval received (irrigation set); management plans to build US revenues to $15-25 million over the next 3-4 years.
China Dumping Persists; DGHS Single-Use Mandate a Long-Term Demand Driver
Over 300 dialysis machines sold in H1 FY 2026-2027 — ~1,250 cumulatively; renal grew 20% YoY in Q2 despite competition from Chinese players, which management confirmed "is still there, nothing has changed."
Anti-dumping case filed end of June 2026 and pursued ~4 months with the government — management sees some movement and said the government "may take some action," but such issues take longer than expected; timing of relief uncertain.
DGHS (Directorate General of Health Services), Government of India, issued a circular in late October 2026 (management recalled 22nd-23rd October), effective immediately, mandating single-use of medical devices — dialyzers were previously reused 4 to 5 times; management expects higher dialyzer demand in the long run but cautioned that on-ground implementation across all states and hospitals will take time given India's size.
India is the bigger renal opportunity — ~90% of the Indian market remains import-driven, supporting full import substitution; the initial focus for the next 12 to 18 months (from the Q2 FY 2026-2027 call) will be more on India, with Southeast Asia being explored as the first overseas renal market (registrations, a 1 to 2-year cycle, already initiated in some markets).
Cardiology milestones — ~18,000 drug-eluting stents implanted as of October 2026; the 2,000-patient SAPIRDS clinical registry has enrolled 1,150 patients, with full enrollment targeted by end of FY27; IVL (sonic pressure-wave technology for calcified arteries) launched in August FY 2026-2027.
Policy backdrop — India has no dedicated medtech ministry (the Pharma Ministry under Chemicals & Fertilizers currently oversees medtech); the government may bring an additional PLI scheme for medtech (the first PLI underperformed as it launched during COVID) alongside an R&D promotion scheme, and wants more make-in-India products and lower imports, with action expected over time.
Brazil Live, UK Projects Staged, Europe Direct Presence in Progress
PolyMed Brazil operationalizing on track — Mr. Renato Roca joined as CEO and first shipments dispatched in October 2026; management said the Brazilian subsidiary is picking up.
Three new UK projects under the direct UK presence — first expected to go live in Q1 (FY unspecified), second in Q4 of FY 2026-2027, and third anticipated in Q3 of FY 2027-2028; established to capture India-UK FTA opportunities.
Direct presence being built in key European markets — as the India-EU trade agreement is operationalized soon; management sees almost 30 new products being added in European markets in FY 2027-2028 through new registrations currently underway.
Europe TAM could exceed a few billion dollars — MD Himanshu Baid indicated tender/procurement values in Europe and the UK for its device categories could be around 1 billion (period unspecified), noting every country follows a different procurement process; management explicitly linked the TAM to the company's wide product range.
Subsidiary synergy benefits beginning FY 2027-2028 — CFO said small European acquired assets can grow 8-10% standalone on a secular basis, moving to mid-teens with procurement, supply chain, distribution and product-development synergies, given 1-3 year regulatory approval lead times (synergy work largely executed in CY 2026).
Infusion mix comfort of 45-50% over the next 4-5 years (through FY 2031-2032) — management expects infusion growth to remain strong as the US expansion (out of India) is infusion-driven.
FY27 Guidance Reaffirmed; Doubling Path to FY30 Intact
FY 2026-2027 guidance reaffirmed — consolidated revenue Rs.2,300-2,400 crores; standalone revenue Rs.1,900-1,950 crores (domestic +20%, international +15%); capex Rs.200-225 crores; Q2-annualized revenue run rate already close to the full-year requirement.
Management "very sure" about meeting the expected range of EBITDA and revenue for FY 2026-2027 — MD Himanshu Baid said Q2 numbers reflect the performance targeted for the full year, with similar or better growth striven for over Q3–Q4 FY 2026-2027.
Revenue doubling by FY30 reaffirmed — management said it is already on that path and is "aggressively working to go beyond" the POLYMED 3.0 vision (timeline unspecified for the extension); FY 2026-2027 described as a big year for adding new customers and products expected to become more productive in FY 2027-2028.
Domestic tracking in line with guidance — +22% in Q2 and >19% in H1 FY 2026-2027, broadly in line with the ~20% guidance set at the beginning of FY 2026-2027.
US policy uncertainty flagged — MD said it is too early to call the impact of post-election US policy changes; the company will monitor developments over the next few months and expects to provide more clarity in Q3 FY 2026-2027.
Capex on track — FY 2026-2027 capex guided at Rs.200-225 crore (responding to an analyst query citing Rs.500 crore, period unspecified), with spend underway across plants to balance capacity.
Watch items — ROW freight/logistics normalization, Middle East/Iran exposure at PendraCare and FenderCare, China dumping relief timing, and US policy clarity all remain open variables for the rest of FY 2026-2027.
Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.
Powered by Cofacto — AI research platform for Indian stocks, every claim cited from primary filings